Why is Guardant Health developing a blood-based approach for CRC detection?

Simply because patients who are not up to date with screening are at greater risk of CRC mortality.5 In fact, over 75% of people who died from CRC were not up to date with screening.5 CRC remains the second-leading cause of cancer-related deaths in the US.6 Sadly, over half of patients are diagnosed after their disease has spread and when survival rates are drastically lower.6-8 A blood-based approach can improve these statistics and increase patient compliance by overcoming barriers associated with available screening options–colonoscopy and stool-based testing.4